LNTH - Lantheus Holdings, Inc.
| Previous Close | 28.26 |
| Open | 28.50 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1300 |
| Day's Range | 27.59 - 28.50 |
| 52 Week Range | 12.59 - 29.80 |
| Volume | 194,448 |
| Avg. Volume | 404,761 |
| Market Cap | 1.074B |
| Beta (3Y Monthly) | 1.81 |
| PE Ratio (TTM) | 25.86 |
| EPS (TTM) | 1.07 |
| Earnings Date | Jul 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.75 |
- Zacks•5 days ago
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•12 days ago
Lantheus Holdings to Host Second Quarter 2019 Earnings Conference Call on July 25, 2019 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 25, 2019, to discuss its financial and operating results for the second quarter of 2019. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 7155758. A live audio webcast of the call will also be available in the Investors section of the Company’s website at www.lantheus.com.
- Simply Wall St.•15 days ago
Is Lantheus Holdings, Inc.'s (NASDAQ:LNTH) CEO Being Overpaid?
Mary Heino has been the CEO of Lantheus Holdings, Inc. (NASDAQ:LNTH) since 2015. First, this article will compare CEO...
- Business Wire•29 days ago
Lantheus Announces Presentation of New Patient Outcomes Data for DEFINITY® at the American Society of Echocardiography 2019 Annual Scientific Sessions
Findings Show Improved Clinical Management and Decreased Length of Stay in Intensive Care Unit Patients Receiving DEFINITY-Enhanced Echocardiography Versus Non-Contrast Echocardiog
- Business Wire•last month
Lantheus Announces New Patient Outcomes Data for DEFINITY® to be Presented at the American Society of Echocardiography 2019 Annual Scientific Sessions
Company will also host a scientific symposium and interactive panel discussion focused on enhanced echocardiography
- Insider Monkey•last month
Here is What Hedge Funds Think About Lantheus Holdings Inc (LNTH)
We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of Lantheus Holdings Inc (NASDAQ:LNTH) based on that […]
- Simply Wall St.•last month
Is It Time To Consider Buying Lantheus Holdings, Inc. (NASDAQ:LNTH)?
Lantheus Holdings, Inc. (NASDAQ:LNTH), which is in the medical equipment business, and is based in United States, saw...
- Business Wire•2 months ago
Lantheus Announces Strategic Collaboration with NanoMab to Provide a Novel Biomarker for Clinical Development and Management of Immuno-Oncology Therapies
Lantheus expands into immuno-oncology and pharmaceutical services business through the license of NanoMab’s NM-01, an anti-PD-L1 imaging biomarker, designed to evaluate tumor immun
- Business Wire•2 months ago
Lantheus Holdings, Inc. to Present at the Jefferies 2019 Global Healthcare Conference
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Mary Anne Heino, President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m.
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Lantheus Holdings Inc (LNTH)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Simply Wall St.•2 months ago
Does Market Volatility Impact Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Share Price?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) then it's worth thinking about how it cont...
- Business Wire•3 months ago
Lantheus Holdings, Inc. to Present at the 2019 UBS Global Healthcare Conference
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Mary Anne Heino, President and Chief Executive Officer, and Robert Marshall, Chief Financial Officer, will present at the 2019 UBS Global Healthcare Conference at 1:00 p.m.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of LNTH earnings conference call or presentation 30-Apr-19 12:00pm GMT
Q1 2019 Lantheus Holdings Inc Earnings Call
Motley Fool•3 months agoLantheus Holdings Inc (LNTH) Q1 2019 Earnings Call Transcript
LNTH earnings call for the period ending March 31, 2019.
- Zacks•3 months ago
Lantheus Holdings (LNTH) Q1 Earnings Top Estimates
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and -0.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Lantheus Holdings: 1Q Earnings Snapshot
The North Billerica, Massachusetts-based company said it had profit of 25 cents per share. Earnings, adjusted for one-time gains and costs, were 28 cents per share. The diagnostic imaging company posted ...
- Business Wire•3 months ago
Lantheus Holdings, Inc. Reports First Quarter 2019 Financial Results
NORTH BILLERICA, Mass.-- -- Worldwide revenues of $86.5 million for the first quarter 2019, representing an increase of 4.7% over the prior year period Net income of $9.9 million for the first quarter 2019, representing an increase of 21.2% over the prior year period GAAP diluted EPS of $0.25 for the first quarter 2019, representing an increase of 20.3% over the prior year period; adjusted diluted ...
- Zacks•3 months ago
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
- Business Wire•3 months ago
Lantheus Holdings to Host First Quarter 2019 Earnings Conference Call on April 30, 2019 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, April 30, 2019, to discuss its financial and operating results for the first quarter of 2019. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 8250839. A live audio webcast of the call will also be available in the Investors section of the Company’s website at www.lantheus.com.
- Simply Wall St.•3 months ago
Is Lantheus Holdings, Inc. (NASDAQ:LNTH) A High Quality Stock To Own?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in...
- MoneyShow•4 months ago
Two Health Favorites- Wound Care to Medical Imaging
Our favorite new stock ideas include two healthcare firms -- one a life sciences play involved in wound care and the other a seller of medical imaging agents, notes Richard Moroney, editor of the small cap focused advisory service, Upside.
- PR Newswire•4 months ago
SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
NEW YORK , April 3, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
- Business Wire•4 months ago
Lantheus Enters Strategic Collaboration with Cerevast for Potential New Eye Care Application Using Microbubbles
Lantheus Holdings, Inc. (the “Company”) (LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with Cerevast Medical, Inc. (“Cerevast”) for the treatment of retinal vein occlusion (RVO), one of the most common causes of vision loss worldwide. This collaboration fits squarely into Lantheus’ growth strategy to identify new applications for its microbubble franchise and expand into new disease areas, such as ocular diseases. Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye.
- Simply Wall St.•4 months ago
The Lantheus Holdings (NASDAQ:LNTH) Share Price Gained 1154% And Shareholders Are Jubilant
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We think that it's fair to say that the possibilityRead More...
